2015

Pulmonary Rehabilitation and Exercise in Pulmonary Arterial Hypertension: An Underutilized Intervention

Sonu Sahni  
*Touro College of Osteopathic Medicine,* sonu.sahni@touro.edu

Barbara Capozzi  
*Touro College of Osteopathic Medicine,* barbara.capozzi@touro.edu

Asma Iftikhar

Vasiliki Sgouras

Marcin Ojrzanowski

*See next page for additional authors*

Follow this and additional works at: [https://touroscholar.touro.edu/tcomny_pubs](https://touroscholar.touro.edu/tcomny_pubs)  
Part of the Osteopathic Medicine and Osteopathy Commons, Pulmonology Commons, and the Rehabilitation and Therapy Commons

**Recommended Citation**


This Article is brought to you for free and open access by the Touro College of Osteopathic Medicine (New York) at Touro Scholar. It has been accepted for inclusion in Touro College of Osteopathic Medicine (New York) Publications and Research by an authorized administrator of Touro Scholar. For more information, please contact carrie.levinson2@touro.edu.
Pulmonary rehabilitation and exercise in pulmonary arterial hypertension: An underutilized intervention

Sonu Sahni1, Barbara Capozzi2, Asma Iftikhar1, Vasiliki Sgouras3, Marcin Ojrzanowski4, Arunabh Talwar1,5,*

1| North Shore - Long Island Jewish Health System, Department of Pulmonary, Critical Care and Sleep Medicine, New Hyde Park, NY, USA
2| Touro College of Osteopathic Medicine, Department of Primary Care, New York, NY, USA
3| Seton Hall University - School of Health and Medical Sciences, South Orange, NJ, USA
4| W. Bieganski Hospital, Department of Cardiology, Łódź, Poland
5| Hofstra North Shore - LIJ School of Medicine, Hofstra University, Hempstead, NY, USA

Pulmonary arterial hypertension (PAH) is a rare and devastating disease characterized by progressive increases in pulmonary arterial pressure and pulmonary vascular resistance which eventually leads to right ventricular failure and death. Early thought process was that exercise and increased physical activity may be detrimental to PAH patients however many small cohort trials have proven otherwise. In addition to the many pharmaceutical options, exercise and pulmonary rehabilitation have also been shown to increase exercise capacity as well as various aspects of psychosomatic health. As pulmonary and exercise rehabilitation become more widely used as an adjuvant therapy patient outcomes improve and physicians should consider this in the therapeutic algorithm along with pharmacotherapy.

Keywords: Pulmonary arterial hypertension, Pulmonary rehabilitation, Six minute walk test, Exercise intolerance, Pulmonary hypertension, Health related quality of life

INTRODUCTION

Pulmonary hypertension is a rare and devastating disease characterized by progressive increases in pulmonary arterial pressure and pulmonary vascular resistance which eventually leads to right ventricular failure and death (Badesch et al., 2009; Farber and Longo, 2004). It may due to various etiologies such as left heart disease, parenchymal lung disease, chronic thromboembolic disease, hematologic disorders or it may be idiopathic in nature (Table 1) (Simonneau et al., 2013) though the clinical picture of these patients is similar. Patients with all forms of pulmonary hypertension present with progressive dyspnea and increasing exercise intolerance. More specifically WHO Group I pulmonary arterial hypertension (PAH) is due to direct injury to the pulmonary vessels and vascular bed. At present there is no cure for PAH, however over the past decade targeted pharmaceutical options have become available. In addition to these pharmaceutical options, exercise and pulmonary rehabilitation have also been shown to increase exercise capacity, WHO functional class, peak oxygen consumption and resting heart rate (Grunig et al., 2011; 2012a). It has also been seen that exercise may improve health related quality of life (HRQoL) (Chan et al., 2013), depression (Verma et al., 2014) and fatigue (Talwar et al., 2014). It is imperative that clinicians use pulmonary rehabilitation and exercise as an adjuvant therapy in the treatment of these patients as its benefits are clearly evident. This review will attempt to emphasize the importance of structured exercise training in the pulmonary hypertension population despite etiology and disease severity.

PULMONARY REHABILITATION

Over the last few decades pulmonary rehabilitation has advanced as a therapeutic option in patients of chronic respiratory disease. Evidence based medicine has determined that pulmonary

*Corresponding author: Arunabh Talwar
North Shore - Long Island Jewish Health System, Department of Pulmonary, Critical Care and Sleep Medicine, 410 Lakeville Rd, New Hyde Park, NY 11040, USA
Tel: +1-516-465-5400, Fax: +1-516-465-5454, E-mail: arunabh@nshs.edu
Received: February 14, 2015 / Accepted: April 8, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pulmonary rehabilitation in pulmonary arterial hypertension

Rehabilitation can reduce dyspnea, increase exercise tolerance and improve health related quality of life in all settings of chronic respiratory disease (Spruit et al., 2013). Pulmonary rehabilitation is defined as a comprehensive intervention based on a thorough patient assessment followed by patient-tailored therapies, which include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence of health-enhancing behaviors (Spruit et al., 2013).

Use of exercise training and pulmonary rehabilitation in cardiopulmonary diseases such as congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) have shown patient outcome improvement and are well described (Hambrecht et al., 1998; Ries et al., 2007). However, in the setting of pulmonary hypertension only small cohorts of studies exist. The use of exercise training and pulmonary rehabilitation in a pulmonary hypertension population is still underutilized though studies have shown its beneficial effect (de Man et al., 2009; Martinez-Quintana et al., 2010).

Table 1. World Health Organization’s classification of pulmonary hypertension (Simonneau et al., 2013)

| Group I - Pulmonary Arterial hypertension (PAH) |  |
|-----------------------------------------------|  |
| Idiopathic PAH                                 |  |
| Heritable PAH (BMPR2, ALK1, ENG, SMAD9, CAV1, KCNK3, Unknown) |  |
| Drug and toxin induced                         |  |
| Associated with (i) Connective tissue disease, (ii) HIV infection, (iii) Portal hypertension, (iv) Congenital heart disease, (v) Schistosomiasis |  |
| Pulmonary veno-occlusive disease and/ or pulmonary capillary hemangiomatosis |  |
| Persistent pulmonary hypertension of the newborn |  |

| Group II - Pulmonary hypertension due to left heart disease |  |
|------------------------------------------------------------|  |
| Left ventricular systolic dysfunction                      |  |
| Left ventricular diastolic dysfunction                     |  |
| Valvular disease                                            |  |
| Congenital/ acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies |  |

| Group III - Pulmonary hypertension due to lung diseases and/or hypoxia |  |
|---------------------------------------------------------------------|  |
| Chronic obstructive pulmonary disease                              |  |
| Interstitial lung disease                                          |  |
| Other pulmonary diseases with mixed restrictive and obstructive pattern |  |
| Sleep disordered breathing                                         |  |
| Alveolar hypoventilation disorders                                 |  |
| Chronic exposure to high altitudes                                 |  |
| Developmental lung disease                                         |  |

| Group IV - Chronic thromboembolic pulmonary hypertension (CTEPH) |  |
|-----------------------------------------------------------------|  |

| Group V - Pulmonary hypertension with unclear multifactorial mechanisms |  |
|------------------------------------------------------------------------|  |

PULMONARY ARTERIAL HYPERTENSION AND EXERCISE IMPAIRMENT

Pulmonary arterial hypertension is characterized by a progressive increase in pulmonary vascular resistance, leading to right ventricular failure and eventual death (Simonneau et al., 2013). Prior to pharmacological intervention traditional therapies were utilized which included anticoagulants, diuretics, and supplemental oxygen. However, after the pathophysiologic process became well known disease-targeted therapies such as phosphodiesterase inhibitors, endothelin receptor antagonists and prostacyclins have become more widely used (Rubin, 2013). Combinations of these agents are used to decrease pulmonary vascular resistance, decrease pulmonary artery pressures and increase exercise tolerance (Pugh et al., 2013). Combination therapy with disease specific drugs has shown symptomatic relief as well as been shown to increase exercise capacity and possibly survival rate in pulmonary hypertension (Ghofrani et al., 2002; Hoeper et al., 2004). Though these medications address quantitative measures of pulmonary vasculature and hemodynamics, exercise capacity and quality of life continue to decline despite optimized treatment.

http://dx.doi.org/10.12965/jer.150190
Exercise capacity is reduced in the setting of pulmonary hypertension which is associated with depression and anxiety disorders as demonstrated by Lowe et al. (2004). Until a better understanding of exercise training in the setting of pulmonary hypertension was established the early thought process was that exercise and increased physical activity may be detrimental to these patients and may actually increase pulmonary pressures expediting the proliferative process (Badesch et al., 2004).

The pathogenesis of pulmonary hypertension is multifactorial. WHO group I pulmonary hypertension, also referred to as pulmonary arterial hypertension is characterized by abnormalities initiating in the small arteries of the pulmonary vasculature, including enhanced cell proliferation and reduced apoptosis, endothelial dysfunction, thrombosis in situ, inflammation, and plexiform arteriopathy, leading to vascular remodeling and excessive vasoconstriction (McLaughlin et al., 2009). This may due to connective tissue diseases, congenital heart disease, HIV infection, portal hypertension, heritable or it may be idiopathic in nature. In the setting of PAH these changes cause resistance for the blood flowing through the pulmonary arteries. This leads to increased pulmonary artery pressures and increased pulmonary vascular resistance pressures eventually leading to right heart failure due to increased afterload, decreased contractility, and reduced cardiac output (Waxman, 2012). The combination of reduced cardiac output and increased pulmonary vascular resistance creates a situation where exertion causes dyspnea and negatively affects quality of life.

Exertional dyspnea being a common symptom across the pulmonary hypertension population provides a method to assess disease severity and progress. Dyspnea may be measures subjectively by using instruments such as the Borg Dyspnea Scale and Medical Research Council Dyspnea Scale (Bestall et al., 1999; Borg, 1970). The severity of exertion is helpful to assess severity and prognosis in pulmonary hypertension. The 6-min walk test and the measure distance is used to assess exercise capacity in patients diagnosed with pulmonary disease and is used as the determinant and primary endpoint in many exercise training clinical trials (ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories, 2002). Exercise tolerance can also be measured using cardiopulmonary exercise testing (American Thoracic, Society/ American College of Chest Physicians, 2003).

**CLINICAL TRIALS OF EXERCISE TRAINING AND PULMONARY REHABILITATION**

Though early thought process advised against increased exertion and exercise a change in thinking brought upon clinical trials of exercise respiratory training in the pulmonary hypertension population (Table 2). In Mereles et al., (2006) conducted the first prospective randomized study to evaluate the effects of exercise on chronically ill pulmonary hypertension patients, stable on medication. Thirty patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension were randomly assigned to either a control or training group. Primary end points were the change in 6-min walk distance from baseline to week 15 in the scores of the Short Form Health Survey quality-of-life questionnaire (SF-36). Secondary endpoints were also assessed. At week 15, patients in the primary and secondary training groups had an improved 6-min walking distance. Exercise training was shown to be well tolerated and improved scores of quality of life, WHO functional class and peak oxygen consumption. Systolic pulmonary artery pressure values at rest did not change significantly after 15 weeks of exercise and respiratory training (Mereles et al., 2006).

Though the ground work for exercise training in pulmonary hypertension was laid out, furthering testing was required. De Man et al. (2009) conducted a trial of exercise on only patients with WHO Group I PAH. Nineteen clinically stable PAH patients with moderate disease underwent exercise training program for 12 weeks in which maximal capacity endurance capacity and quadriceps function were assessed and serial quadriceps muscle biopsies were obtained. 6-min walk distance and peak exercise capacity did not change after training. However, endurance capacity improved significantly after training. Training also enhanced aerobic capacity of the quadriceps, by increasing capillarization (de Man et al., 2009).

A study by Fox et al. (2011) of 22 PAH or CTEPH patients demonstrated significant increase in 6 MWD as well as Peak VO₂. The rehabilitation program consisted of 24 1-h sessions of exercise training/rehabilitation over the course of 12 weeks. Peak work rate during cardiopulmonary exercise test also increased in the rehabilitation group with borderline significance. Echocardiography and blood N-terminal pro-brain natriuretic peptide levels were unchanged. No adverse events occurred due to the rehabilitation program demonstrating safety.

With evidence of the positive benefits of exercise training in the setting of pulmonary hypertension further clinical trials were conducted. Grunig et al. (2011) demonstrated the benefits of exercise training in a connective tissue disease population with pulmonary hypertension (Grunig et al., 2012b). Patients with RHC confirmed connective tissue disease related pulmonary hypertension received in-hospital exercise training for 3 weeks which was con-
continued for another 12 weeks at home. Patients improved the mean distance walked in 6 min, resting heart rate, peak oxygen consumption, and oxygen saturation. In addition systolic pulmonary artery pressure, and diastolic systemic blood pressure improved significantly after 3 weeks of exercise training. The 1- and 2-yr overall-survival rates were found to be 100%, the 3-yr survival rate 73% (Grunig et al., 2012a).

Another study by Grunig et al. (2011) aimed to assess disease progression and survival in patients with severe chronic pulmonary hypertension. Fifty eight patients with severe pulmonary hypertension on stable medication received exercise and respiratory training in hospital for 3 weeks which was later continued at home. They were prospectively followed for 24±12 months. Primary endpoints were time to clinical worsening and survival. Adverse events and changes in the 6-min walking test, QoL, WHO functional class and gas exchange were secondary endpoints and were evaluated at baseline and at weeks 3 and 15. The results showed that all patients tolerated the exercise training well without any severe adverse events. In week 15, 6-min walking test results were significantly improved compared to baseline as well as quality of life scores, WHO functional class, peak oxygen consumption, heart rate at rest and maximal workload. Survival at 1 and 2 yr was 100 and 95%, respectively (Grunig et al., 2011).

Fifteen events occurred during the follow-up. It was concluded that exercise and respiratory training as add-on to medical treatment may improve exercise capacity and QoL, with a good long term safety profile.

### NON PHYSICAL EFFECTS OF EXERCISE AND PULMONARY REHABILITATION

As pulmonary hypertension’s most debilitating manifestation is exercise intolerance most trials focus on improvement in this characteristic as well as hemodynamics. However, in addition to physical improvement, there is a great deal of improvement in aspects of psychosomatic domains. It is well known that patients with pulmonary hypertension experience depression (Verma et al., 2014) and report increased levels of fatigue severity (Talwar et al., 2014). It is also well known that these patients have a severely impaired health related quality of life (Taichman et al., 2005). These aspects of psychosomatic medicine may also be addressed with the use of structured pulmonary rehabilitation and exercise programs in this population. A study by Kim et al. (2013) showed the effects that dyspnea has on depression and health related quality of life (HRQoL). Pulmonary rehabilitation programs have also showed improvement in fatigue severity as well as depression (Talwar et al.,

---

**Table 2. Summary of exercise testing trial in the setting of pulmonary hypertension**

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Study Design</th>
<th>Intervention</th>
<th>Duration of Exercise/Rehab Program</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mereles et al., 2006</td>
<td>30</td>
<td>RCT</td>
<td>Bicycle training, Walking, Dumbbell, Respiratory Training</td>
<td>3 week in hospital + 12 weeks at home</td>
<td>Improvement in 6MWD, QOL scores, WHO FC, VO, (peak +AT) and workload. No change in SPAP; No SAE</td>
</tr>
<tr>
<td>De Man et al., 2009</td>
<td>19</td>
<td>Non-randomized single group</td>
<td>Bicycle Training, Quadriceps stretch and endurance</td>
<td>12 weeks in rehabilitation center</td>
<td>Stable 6MWD, peak exercise capacity. Increased muscle strength, capillaries in muscle, oxidative enzyme activity.</td>
</tr>
<tr>
<td>Chan et al., 2013</td>
<td>23</td>
<td>RCT</td>
<td>Treadmill walking only for 30-45 min.</td>
<td>10 weeks 24-30 session in rehabilitation facility</td>
<td>Increase in 6MWD, QOL scores, Time to exercise intolerance, Peak work rate; No SAE</td>
</tr>
<tr>
<td>Fox et al., 2010</td>
<td>22</td>
<td>NRCT</td>
<td>1 hr. per session, aerobic interval training, bicycle, treadmill, walking, step climbing; resistance training.</td>
<td>12 weeks in outpatient rehabilitation center</td>
<td>Increase in 6MWD, Peak VO2, Peak WR, BNP, SPAP and CO remained the same; No SAE</td>
</tr>
<tr>
<td>Grunig et al., 2011</td>
<td>58</td>
<td>NRCT single group</td>
<td>Daily bicycle training, dumbbell training, respiratory training</td>
<td>3 weeks in hospital, 12 week at home</td>
<td>Increased 6MWD, QOL scores, WHO FC, Peak VO2, Maximum workload and decreased resting HR; No SAE</td>
</tr>
<tr>
<td>Grunig et al., 2012</td>
<td>183</td>
<td>NRCT single group</td>
<td>Daily interval bicycle training, walking, dumbbell training, mental training, home</td>
<td>3 weeks in hospital, 12 week at home</td>
<td>Increased 6MWD, QOL scores, WHO FC, Peak VO2, Decreased resting heart rate, and SPAP; No SAE</td>
</tr>
<tr>
<td>Grunig et al., 2012</td>
<td>21</td>
<td>NRCT single group</td>
<td>Daily interval bicycle training, walking, dumbbell training, mental training, home training</td>
<td>3 weeks in hospital, 12 week at home</td>
<td>Increased 6MWD, QOL scores, WHO FC, Peak VO2, Maximum workload increased O2; SPAP, Survival at 2 yr-100%, 3 yr 73%</td>
</tr>
</tbody>
</table>

RCT, Randomized Controlled Trial; 6MWD, 6 min walk distance; QOL, Quality of life; WHO-FC, World Health Organization Functional Class; SAE, Serious Adverse Events; NRCT, Non-Randomized Control Trial; HR, Heart Rate; BNP, Brain Natriuretic Peptide; SPAP, Systolic Pulmonary Artery Pressure.
CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES


Grunig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Stae

Grunig E, Maier F, Ehlken N, Fischer C, Lichtblau M, Blank N, , Fein C, Stöckl F, Prange F, Stae


Martinez-Quintana E, Miranda-Calderin G, Ugarte-Lopetegui A, Rodri


Rubin LJ. Pulmonary hypertension: current management and future di

p):D34-41.


Verma S, Cardenas-Garcia J, Mohapatra PR, Talwar A. Depression in pul